United States
Home
P&G Network Search
Pharmaceuticals:
US Products
Consumers:
Health Care Professionals:
FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS
CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of ActonelŽ (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

Actonel Testimonial

  Living With Osteoporosis






Osteoporosis

      

"I was told that I had severe osteoporosis
and there is a 99% chance I would get fractures."



Find out more about how Procter & Gamble Pharmaceuticals is creating a world of difference in people's lives everyday. Click below to view the following testimonials.

Asacol Testimonial
Fighting Ulcerative Colitis

"When I was first diagnosed with ulcerative colitis, I just was at a loss to know what to do."

Dantrium Testimonial
It's a Matter of Life or Death

"We arrive into the recovery room there. Andrew is white as a ghost. He had just visited death's door....Luckily, they had it available at the hospital, and administered it quickly..... Slowly, Andrew came back to us."


Touching lives, improving life. P&G


©2008 Procter & Gamble. All claims valid only in the U.S.  Legal Information  Privacy Statement  P&G Links

BBBOnLine Reliability Seal